EPO and chronic kidney disease: The majority of aspects related to the monitoring and therapeutic management of CKD were either considered in only a small proportion of affected individuals (e.g., quantification of PTH/25-OH-D3/transferrin saturation) or avoided at all (e.g., recommendation of erythropoietin and documentation of CKD-MBD diagnosis).